Damien Alan Perriman, Chief Commercial Officer of Exozymes Inc. (NASDAQ:EXOZ), filed a Form 4 on October 26, 2026, disclosing the vesting of restricted stock units and a subsequent sale of common stock on October 12, 2026.

Key Highlights

  • RSU conversion: On October 9, 2026, Perriman converted 3,922 restricted stock units into 3,922 shares of common stock on a one-for-one basis, with no consideration paid on conversion.
  • Shares sold: On October 12, 2026, Perriman sold 3,729 shares at a weighted average price of $5.2096 per share.
  • Sale price range: The shares were sold in multiple trades at prices ranging from $5.15 to $5.25 per share, according to the filing.
  • Purpose of sale: According to the filing, the shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
  • Remaining ownership: Following the transactions, Perriman directly held 28,692 shares of common stock and 39,225 restricted stock units.
  • Original grant: The filing states that on April 1, 2026, Perriman was granted an aggregate of 62,759 restricted stock units, vesting periodically.

Perriman RSU Vesting and Tax-Related Sale at Exozymes

According to the Form 4 filed with the SEC, Damien Alan Perriman, serving as Chief Commercial Officer of Exozymes Inc., reported two transactions in the company's common stock. On October 9, 2026, 3,922 restricted stock units converted into an equal number of shares of common stock. The filing notes that no consideration was paid by the reporting person upon conversion, and that the units were part of a grant of 62,759 restricted stock units made on April 1, 2026, which vest periodically.

Three days later, on October 12, 2026, Perriman disposed of 3,729 shares at a weighted average price of $5.2096 per share. The filing describes the sale as being made "to cover tax withholding obligations in connection with the vesting of restricted stock units." The shares were sold across multiple trades at prices ranging from $5.15 to $5.25 per share. The filing states that Perriman will provide full information on the number of shares sold at each separate price upon request from the issuer, any security holder, or SEC staff.

After these transactions, the filing reports that Perriman directly owned 28,692 shares of common stock and retained 39,225 restricted stock units. Both the common stock holdings and the derivative securities are reported as directly owned. The Form 4 was signed by Damien Perriman and dated October 26, 2026.

What Was Disclosed

Exozymes Inc.'s Chief Commercial Officer Damien Alan Perriman disclosed the vesting of 3,922 restricted stock units and the sale of 3,729 common shares at a weighted average of $5.2096, with the sale attributed to tax withholding obligations, leaving him with 28,692 shares directly held.